Modakafusp alfa

莫卡芙普-α

Report date: 2022/07/08 10:18:47

Base Information

Drug NameModakafusp alfa
Drug Alias NameTEV-48573TAK-573
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsInterferon alpha/beta receptor agonists
TargetsLymphocyte differentiation antigen CD38Interferon alpha/beta receptor
Therapy Area/IndicationsMultiple MyelomaMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdTakeda Development Center Americas Inc
Inactive CompaniesTeva Branded Pharmaceutical Products R&D LLC
Active IndicationsMultiple Myeloma
Inactive IndicationsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A